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Edited by Ivan SadowskiAbstract Prospero-related homeobox protein (Prox1) plays
essential roles in the development of many tissues and organs.
In the present study, we show that Prox1 is modiﬁed by the small
ubiquitin-like protein SUMO-1 in cultured cells. Mutation anal-
ysis identiﬁed at least four potential sumoylation sites within the
repression domain of Prox1. Our data indicate that sumoylation
of Prox1 reduces its interaction with HDAC3 and as a result
downregulates its corepressor activity. These ﬁndings suggest
that sumoylation may serve as a novel mechanism for the regu-
lation of Prox1s corepressor activity.
Structured summary:
MINT-6787569:
PROX1 (uniprotkb:Q92786) physically interacts (MI:0218)
with HDAC3 (uniprotkb:O15379) by anti tag coimmunoprecip-
itation (MI:0007)
MINT-6787767:
PROX1 (uniprotkb:Q92786) physically interacts (MI:0218)
with SUMO-1 (uniprotkb:P63165) by anti tag coimmunopre-
cipitation (MI:0007)
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Transcription1. Introduction
The homeoprotein prospero-related homeobox (Prox1) is a
vertebrate homologue of Drosophila melanogaster Prospero.
Functional inactivation of mouse prox1 has demonstrated a
critical role of Prox1 in the development of lens, retina, liver,
pancreas, and lymphatic vasculature [1–5]. Previous work
showed that Prox1 could interact with LRH-1 and downregu-Abbreviations: DBD, DNA binding domain; HDAC, histone deace-
tylase; LRH-1, liver receptor homologue 1; PIAS, protein inhibitor of
activated STAT; Prox1, prospero-related homeobox; SHP, small
heterodimer partner; SSP3, SUMO-1 speciﬁc peptidase 3; SUMO,
small ubiquitin-related modiﬁer
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terol 7-alpha hydroxylase (cyp7a1) and small heterodimer
partner (shp) [6,7]. How the corepressor activity of Prox1 is
regulated, however, has not been addressed in detail yet.
Small ubiquitin-related modiﬁer (SUMO) is a family of
ubiquitin-like proteins that can be covalently attached to tar-
get proteins through the formation of isopeptide bonds with
speciﬁc lysine residues on target proteins [8]. Sumoylation is
a dynamic process, readily reversed by speciﬁc isopeptidases
such as members of the SENP family that remove the SUMO
moieties from sumoylated proteins [9]. Protein sumoylation
has been shown to aﬀect protein stability, protein–protein
interaction and protein subcellular localization and is involved
in the regulation of transcription, DNA repair as well as gen-
ome integrity [10–12]. As a transcription regulatory mecha-
nism, sumoylation of many transcription factors has been
associated with transcriptional repression [10]. In a limited
number of cases such as p53, Tcf4, and Ikaros, protein sumoy-
lation results in transcriptional activation or derepression [13–
15].
Here we provide the evidence on the sumoylation of Prox1
in cells. Several lysines within the repression region of Prox1
can be modiﬁed by SUMO-1. Sumoylation of Prox1 can atten-
uate its interaction with HDAC3, and by doing so, downregu-
lates the transcriptional corepressor activity of Prox1.2. Methods
2.1. Expression plasmids
Expression plasmids of Flag, hemagglutinin (HA) or Myc-tagged
Prox1, HDAC2, HDAC3 (generous gifts from Dr. Seto), and
SUMO-1 (obtained by PCR from Huh7 cDNAs) were constructed
using pcDNA3 as vector (Invitrogen Life Technologies, Carlsbad,
USA). SUMO-1(D6) with the C-terminal six residues of SUMO-1 de-
leted was generated by PCR. For the expression of Gal4-DBD-Prox1
and GFP-SUMO-1, cDNAs of Prox1 and SUMO-1 were inserted into
pM and pEGFP-C1 (Clontech, Palo Alto, USA), respectively. Prox1
mutants were generated by standard PCR-based mutagenesis. Human
SSP3 cDNA was obtained by PCR and cloned into pcDNA3.1/Myc-
His()-A (Invitrogen). The pG5-Luc reporter containing ﬁve tandem
repeats of the Gal4 binding site has been described previously [16].
The shp-Luc reporter was constructed by inserting the human shp gene
promoter (nucleotides 572 to +10) into pGL2-Basic (Promega,
Madison, USA). Prox1-targeting siRNA expression plasmid pSuper-
Prox1(1830) was created using pSuper vector (OligoEngine) to target
the agttcaacagatgcattac site on Prox1. To create the Prox1 mutant
(1830m) not targeted by the siRNA, the above site was mutated to
aatttaatcgctgtatcac.blished by Elsevier B.V. All rights reserved.
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The polyclonal anti-Prox1 antibody and monoclonal anti-HA anti-
body were purchased from Upstate and Santa Cruz Biotechnology,
Inc., Santa Cruz, USA, respectively. The anti-Flag (M2) monoclonal
antibody was product of Sigma (Sigma, St. Louis, USA).
2.3. Luciferase reporter assay
In a typical reporter assay, cells were cotransfected with 0.3 lg of a
promoter luciferase reporter, 0.6 lg of an expression plasmid, and
0.05 lg of pCMV-lacZ (Promega) encoding b-galactosidase as an
internal control to normalize transfection eﬃciencies. Luciferase and
b-galactosidase activities were performed as described previously [16].
2.4. Reverse transcription and real-time quantitative PCR
Total mRNA was prepared using Trizol (Invitrogen). After cDNA
synthesis, cDNA products were assayed by real-time quantitative
PCR with primers as follows: for b-actin, 5 0-GAAGGTGAAGGTCG-
GAGTC-30 and 5 0-TCACACTTCATGATGGAGTTG-30; for shp, 5 0-
CAAGAAGATTCTGCTGGAGG-30 and 5 0-GGATGTCAACATC-
TCCAATG-30. The b-actin gene was used as an internal control.
2.5. Immunoprecipitation and Western analysis
Whole cell extracts were prepared by lysing cells with modiﬁed RIPA
buﬀer (50 mM Tris–HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5%
NP-40, 0.1% sodium deoxycholate) and a cocktail of protease inhibi-
tors. When appropriate, all solutions contained 20 mM N-ethylmalei-
mide (NEM, Sigma) to inhibit SUMO isopeptidases. For
immunoprecipitation, cell extracts were incubated with antibody of tar-
get proteins and protein A-sepharose (Amersham Pharmacia Biotech,
Uppsala, Sweden). Bound proteins were released in 2· SDS sample buf-
fer, resolved on 8% SDS–PAGE gel, and analyzed by immunoblotting
using corresponding antibodies. To detect HA-HDAC3, Mouse IgG
TrueBlot (eBioscience, USA) was used as secondary antibody. Wes-
tern Blot Luminol Reagent (Santa Cruz) was used for signal detection.Fig. 1. Sumoylation of Prox1 in cells. (A) Sumoylation of the
endogenous Prox1 in Huh7 cells. HEK293T cells lack endogenous
Prox1 expression and serve as negative control. Su-Prox1: sumoylated
Prox1. WB: Western blot. (B) Sumoylation of Prox1 in HEK293T
cells. Cells were cotransfected with the expression plasmids of HA-
Prox1 and Flag-SUMO-1 or Flag-SUMO-1(DC6). HA-Prox1 was
precipitated with the anti-HA antibody and analyzed with the anti-
Prox1 and anti-Flag antibodies. Expression of indicated proteins in
whole cell lysates (WCL) were examined with the corresponding
antibodies. (C) Sumoylation of Prox1 in Huh7 is enhanced by SUMO-
1 and reduced by SSP3. Prox1 was analyzed with the anti-Prox1
antibody. The expression of Myc-SSP3 was examined with the anti-
Myc antibody.3. Results
3.1. Modiﬁcation ofProx1 by SUMO-1 in cultured cells
While using anti-Prox1 antibody to detect endogenous
Prox1 expression in human hepatoma cell line Huh7, we found
that in addition to the 80 kDa band corresponding to full-
length Prox1, bands with higher apparent molecular weights
were also detected. (Fig. 1A). A similar pattern of Prox1 sig-
nals was also observed using another human hepatoma cell
line HepG2, which also endogenously expresses Prox1 (data
not shown). None of these signals were detected in HEK293T
cells, which lack endogenous Prox1 expression (Fig. 1A). Since
the pattern is very similar to those reported for proteins mod-
iﬁed by sumoylation, we went on to examine such a possibility.
HA-Prox1 was coexpressed with Flag-SUMO-1 or Flag-
SUMO-1(DC6) in HEK293T cells. SUMO-1(DC6) is a
SUMO-1 mutant lacking six C-terminal amino acid residues
and consequently unusable for sumoylation [17]. HA-Prox1
proteins were immunoprecipitated by anti-HA monoclonal
antibody. In addition to the 80 kDa band, bands with higher
apparent molecular weights were detected by anti-Prox1 when
Flag-SUMO-1 was coexpressed, and these higher molecular
weight bands, but not the 80 kDa band, reacted with anti-
Flag antibody (Fig. 1B). The pattern is highly similar to what
was observed in Huh7 cells (Fig. 1A). No higher molecular
weight bands were detected when Flag-SUMO-1 (DC6) was
coexpressed.
Since SUMO modiﬁcation is a dynamic and reversible pro-
cess, SUMO-1 and SUMO speciﬁc isopeptidases SSP3 [18]
were overexpressed in Huh7 cells. As shown in Fig. 1C, higher
molecular weight bands of Prox1 intensiﬁed with SUMO-1overexpression but became hardly detectable in the presence
of SSP3 overexpression.
Taken together, the above data indicate that Prox1 could
undergo SUMO-1 modiﬁcation in cultured cells.
3.2. Identiﬁcation of Prox1 sites involved in sumoylation
Analysis of the Prox1 protein sequence with the consensus
sumoylation motif WKXE (K is the lysine residue that is mod-
iﬁed; X is any residue) revealed four putative sumoylation
sites, namely K232, K326, K353 and K556, all located in the
repression domain (Fig. 2A). To determine which lysine(s)
could be modiﬁed by SUMO-1, Prox1 mutants were generated
with one or two potentially sumoylated lysine residues mutated
to arginine. Each mutant was then coexpressed with SUMO-1
Fig. 2. Identiﬁcation of potential sumoylation sites in Prox1. (A) Schematic representation of the domain organization of Prox1. The potential
sumoylation sites are indicated (a–d) with the lysines underlined. NR1 and 2: the LXXLL-like motifs required for the interaction between Prox1 and
LRH-1. (B) Mutation analysis of the potential sumoylation sites. Myc-SUMO-1 was coexpressed with the Flag-tagged wild-type Prox1 (wt) or one of
the mutants containing a single or double altered sumoylation site(s) (a: K232R; b: K326R; c: K353R; d: K556R). Prox1 was precipitated with the
anti-Flag antibody and analyzed with the anti-Prox1 antibody. The sumoylated forms of Prox1 (S1–S4) are indicated. WB: Western blot.
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using the anti-Prox1 antibody. As shown in Fig. 2B, the
95 kDa form (s1) of Prox1 disappeared when and only when
K556 is mutated (d/ad/bd/cd), suggesting that s1 is most likely
mono-sumoylated at K556. On the other hand, K353 (c) is re-
quired for the formation of s2, since none of the c mutants (c/
ac/bc/cd) gave rise to s2 signals. K232 (a site) and K326 (b site)
do not appear to be as crucial as c and d sites because mutation
of either of them alone did not signiﬁcantly change the overall
sumoylation pattern (a/b). However, they also contribute to
the sumoylation of Prox1 as manifested by altered sumoyla-
tion patterns of several double mutants (ab/ac/ad/bc/bd).
Two double mutants (K326R/K556R and K353R/K556R) dis-
played a total loss of any detectable slow-migrating bands (bd/
cd). These data indicate that modiﬁcation of Prox1 by SUMO-
1 most likely involves multiple lysine residues within the
repression domain. In addition, K556 and K353 appear to
be more important than others. Based on this, the K353R/
K556R double mutant (Prox1cd) was used as sumoylation-
deﬁcient mutant Prox1 in the following studies.
3.3. Sumoylation downregulates the corepressor activity of
Prox1
The possible eﬀects of sumoylation on the corepressor activ-
ity of Prox1 were then analyzed using reporter assays. Expres-
sion plasmid encoding Gal4DBD fused with wild-type Prox1 or
Prox1cd was cotransfected into HEK293T cells with 5xGal4-
Luc reporter. Gal4-Prox1 repressed the expression of the repor-ter gene as expected [6], whereas the sumoylation-deﬁcient
Gal4-Prox1cd displayed even stronger repression (Fig. 3A).
Similar results were obtained using the promoter of human
shp gene, a target gene of LRH-1 [6,19] in Huh7 cells (Fig. 3B).
To examine whether sumoylation of Prox1 aﬀects its core-
pressor activity on an endogenous target gene in vivo, endo-
genous Prox1 expression in HepG2 was knocked-down by
stable transfection of Prox1-targeting siRNA 1830 and trans-
fected cells were selected and maintained with G418.
(Fig. 3C). The obtained cell line HepG2(1830) was then trans-
fected with expression plasmids of Prox1(1830m) or
Prox1(cd + 1830 m), which have mutated 1830 sites and are
therefore not targeted by stably transfected 1830 siRNA
(Fig. 3D, left panel). Endogenous shp mRNA level was deter-
mined by real-time PCR. As shown in Fig. 3D right panel
(black bars), shp mRNA decreased by 20% when
Prox1(1830 m) was expressed. Even more signiﬁcant repres-
sion (60%) of shp was observed when sumoylation-deﬁcient
Prox1(cd + 1830 m) was expressed. This is consistent with data
obtained with overexpression and reporter assays in Huh7 cells
(Fig. 3A and B). Taken together, these results demonstrate
that sumoylation downregulates the corepressor activity of
Prox1.
3.4. Sumoylation of Prox1 interferes with its recruitment of
HDAC3
One of the mechanisms involved in Prox1 corepressor activ-
ity has been proposed to be its recruiting of HDAC3 to target
Fig. 3. Sumoylation downregulates corepressor activity of Prox1. (A) Reporter analysis using 5·Gal4-Luc reporter in HEK293T cells. Control cells
were transfected with the pM vector encoding Gal4-DBD. (B) Reporter analysis using shp-Luc reporter in Huh7 cells. Control cells were transfected
with empty pcDNA3 vector. Relative fold of activation compared to control cells is presented. The means ± S.D. of results from three separate assays
are shown. (C) HepG2 cell line stably transfected with siRNA expression plasmid pSuper-Prox1(1830). Prox1 knockdown was conﬁrmed by western
blot. (D) Transfection of HepG2(1830). (left) Prox1 mRNA was measured by qRT-PCR after transfection of wild-type or mutant Prox1. (right)
expression of GAPDH and Prox1 target gene shp was measured by qRT-PCR. b-actin was used as internal control.
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we conﬁrmed the interaction between Prox1 and HDAC3
(Fig. 4A). We wondered whether sumoylation of Prox1 had
any eﬀects on its recruitment of HDAC3. As shown in
Fig. 4B, Myc-SUMO-1 co-expression resulted in a signiﬁcant
increase in the ratio of sumoylated forms of Prox1 against
unmodiﬁed Prox1 and a concurrent signiﬁcant decrease in
co-immunoprecipitated HDAC3. In contrast, when sumoyla-
tion-deﬁcient Prox1cd was used, Myc-SUMO-1 co-expression
had no obvious eﬀects on its interaction with HDAC3
(Fig. 4C). Taken together, these results suggest that sumoyla-
tion of Prox1 reduces its recruitment of HDAC3.4. Discussion
Vertebrate SUMO family consists of three known members,
namely SUMO-1, SUMO-2 and SUMO-3. Data presented inthis paper demonstrate that endogenous Prox1 is modiﬁed
by SUMO-1, but it cannot be ruled out that Prox1 may also
be modiﬁed by SUMO-2/3. Previous work has shown that
some target proteins are predominantly modiﬁed by either
SUMO-1 or SUMO-2/3, while others are modiﬁed by both
[20].
Sumoylation of target proteins is catalyzed by E1, E2 and E3
enzymes. Our preliminary work identiﬁed two ubiquitous E3
ligases of the PIAS family, PIAS1 and PIAS3, which interact
with Prox1 and promote its sumoylation in HEK293T (data
not shown). The PIAS family proteins were ﬁrst identiﬁed as
inhibitors of signal transducers of activated transcription fac-
tors (STAT) [21,22]. It would be interesting to see whether
PIAS1 and PIAS3 aﬀect endogenous Prox1 sumoylation and
functions in hepatocytes.
How sumoylation interferes with Prox1-HDAC3 interaction
remains to be elucidated. A simple explanation would be that
sumoylation negatively aﬀects the accessibility of the Prox1
Fig. 4. Sumoylation of Prox1 downregulates its interaction with HDAC3. Immunoprecipitations were carried out with the anti-Flag aﬃnity gel. The
precipitations were detected with anti-Prox1 and anti-HA antibody. Expression of indicated proteins in whole cell lysates were examined with this
two antibodies. (A) Flag-Prox1 was coexpressed with HA-HDAC2 or HA-HDAC3 in HEK293T cells. Interaction between Prox1 and HDAC3 was
detected. (B) Flag-Prox1 and HA-HDAC3 were coexpressed with or without Myc-SUMO-1 in HEK293T cells. Sumoylation reduces the interaction
of Prox1 with HDAC3. (C) Same as in (B) except that Prox1cd was overexpressed instead of Prox1. SUMO-1 co-expression had no obvious eﬀects on
the interaction of Prox1 with HDAC3. Su-Prox1: sumoylated Prox1. WB: Western blot.
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of the SUMO moiety may cause Prox1 to assume conforma-
tions more suitable for the binding by other factors, which in
turn prevent association of HDAC3 with Prox1. Furthermore,
since sumoylation can act through a cycle of sumoylation and
desumoylation instead of causing a persistent attachment of
SUMO to the substrate, it has been suggested that seemingly
identical unmodiﬁed protein molecules may have diﬀerent
properties and functions depending on whether or not they
have a history of SUMO modiﬁcation [11]. The molecular de-
tails of how sumoylation of Prox1 impairs its interaction with
HDAC3 certainly warrant further investigation.
Acknowledgments: The authors are grateful to Dr. Seto for expression
plasmids of HDAC2 and HDAC3, This work is supported by the Basic
Research Program from MOST of China (2005CB522402), NNSF
(30393112, 30670434), and Shanghai municipal STC (044107019,
06QH14014).References
[1] Wigle, J.T., Chowdhury, K., Gruss, P. and Oliver, G. (1999)
Prox1 function is crucial for mouse lens–ﬁbre elongation. Nat.
Genet. 21, 318–322.
[2] Sosa-Pineda, B., Wigle, J.T. and Oliver, G. (2000) Hepatocyte
migration during liver development requires Prox1. Nat. Genet.
25, 254–255.
[3] Hong, Y.K., Harvey, N., Noh, Y.H., Schacht, V., Hirakawa, S.,
Detmar, M. and Oliver, G. (2002) Prox1 is a master control gene
in the program specifying lymphatic endothelial cell fate. Dev.
Dyn. 225, 351–357.
[4] Dyer, M.A., Livesey, F.J., Cepko, C.L. and Oliver, G. (2003)
Prox1 function controls progenitor cell proliferation and hori-
zontal cell genesis in the mammalian retina. Nat. Genet. 34, 53–
58.
[5] Wang, J., Kilic, G., Aydin, M., Burke, Z., Oliver, G. and Sosa-
Pineda, B. (2005) Prox1 activity controls pancreas morphogenesis
and participates in the production of ‘‘secondary transition’’
pancreatic endocrine cells. Dev. Biol. 286, 182–194.
3728 S. Shan et al. / FEBS Letters 582 (2008) 3723–3728[6] Steﬀensen, K.R., Holter, E., Bavner, A., Nilsson, M., Pelto-
Huikko, M., Tomarev, S. and Treuter, E. (2004) Functional
conservation of interactions between a homeodomain cofactor
and a mammalian FTZ-F1 homologue. EMBO Rep. 5, 613–
619.
[7] Qin, J., Gao, D.M., Jiang, Q.F., Zhou, Q., Kong, Y.Y., Wang, Y.
and Xie, Y.H. (2004) Prospero-related homeobox (Prox1) is a
corepressor of human liver receptor homolog-1 and suppresses the
transcription of the cholesterol 7-hydroxylase gene. Mol. Endo-
crinol. 18, 2424–2439.
[8] Lee, G.W., Melchior, F., Matunis, M.J., Mahajan, R., Tian, Q.
and Anderson, P. (1998) Modiﬁcation of Ran GTPase-activating
protein by the small ubiquitin-related modiﬁer SUMO-1 requires
Ubc9, an E2-type ubiquitin-conjugating enzyme homologue. J.
Biol. Chem. 273, 6503–6507.
[9] Melchior, F., Schergaut, M. and Pichler, A. (2003) SUMO:
ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28,
612–618.
[10] Hay, R.T. (2005) SUMO: a history of modiﬁcation. Mol. Cell 18,
1–12.
[11] Johnson, E.S. (2004) Protein modiﬁcation by SUMO. Annu. Rev.
Biochem. 73, 355–382, (Review).
[12] Gill, G. (2005) Something about SUMO inhibits transcription.
Curr. Opin. Genet. Dev. 15, 536–541.
[13] Rodriguez, M.S., Desterro, J.M., Lain, S., Midgley, C.A., Lane,
D.P. and Hay, R.T. (1999) SUMO-1 modiﬁcation activates the
transcriptional response of p53. EMBO J. 18, 6455–6461.
[14] Yamamoto, H., Ihara, M., Matsuura, Y. and Kikuchi, A. (2003)
SUMOylation is involved in beta-catenin-dependent activation of
Tcf-4. EMBO J. 22, 2047–2059.[15] Gomez-del Arco, P., Koipally, J. and Georgopoulos, K. (2005)
Ikaros sumoylation: switching out of repression. Mol. Cell Biol.
25, 2688–2697.
[16] Xu, P.L., Liu, Y.Q., Shan, S.F., Kong, Y.Y., Zhou, Q., Li, M.,
Ding, J.P., Wang, Y. and Xie, Y.H. (2004) Molecular mechanism
for the potentiation of the transcriptional activity of human liver
receptor homolog 1 by steroid receptor coactivator-1. Mol.
Endocrinol. 18, 1887–1905.
[17] Lee, Y.S., Jang, M.S., Lee, J.S., Choi, E.J. and Kim, E. (2005)
SUMO-1 represses apoptosis signal-regulating kinase 1 activation
through physical interaction and not through covalent modiﬁca-
tion. EMBO Rep. 6, 949–955.
[18] Girdwood, D., Bumpass, D., Vaughan, O.A., Thain, A., Ander-
son, L.A., Snowden, A.W., Garcia-Wilson, E., Perkins, N.D. and
Hay, R.T. (2003) P300 transcriptional repression is mediated by
SUMO modiﬁcation. Mol. Cell 11, 1043–1054.
[19] Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A.,
Auwerx, J. and Mangelsdorf, D.J. (2000) Molecular basis for
feedback regulation of bile acid synthesis by nuclear receptors.
Mol. Cell 6, 507–515.
[20] Vertegaal, A.C.O., Andersen, J.S., Ogg, S.C., Hay, R.T., Mann,
M. and Lamond, A.I. (2006) Distinct and overlapping sets of
SUMO-1 and SUMO-2 target proteins revealed by quantitative
proteomics. Mol. Cell. Proteom. 5, 2298–2310.
[21] Liu, B., Liao, J., Rao, X., Kushner, S.A., Chung, C.D., Chang,
D.D. and Shuai, K. (1998) Inhibition of Stat1-mediated gene
activation by PIAS1. Proc. Natl. Acad. Sci. USA 95, 10626–10631.
[22] Liu, B., Gross, M., ten Hoeve, J. and Shuai, K. (2001) A
transcriptional corepressor of Stat1 with an essential LXXLL
signature motif. Proc. Natl. Acad. Sci. USA 98, 3203–3207.
